Opioid Dependence Clinical Trial
Official title:
Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
Opioid dependence is a substantial problem associated with significant morbidity and
mortality. Extended-release naltrexone has been found effective at reducing opioid use and
maintaining abstinence, but its use has been limited by the difficulties encountered with
treatment initiation, which involves detoxification from opioids and oral naltrexone
titration. Improving the likelihood of a successful transition to naltrexone is therefore an
important public health goal.
N-methyl-D-aspartate receptor (NMDA) antagonism has been found to alleviate the signs and
symptoms of withdrawal from opioids, as well as to address adaptations associated with
chronic opioid use, such as opioid-induced hyperalgesia (increased pain sensitivity). These
benefits may persist for at least 72 hours after a single dose. NMDA antagonism may therefore
facilitate a rapid transition to naltrexone by reducing discomfort, improving motivation, and
ameliorating adaptations associated with drug dependence, such as craving and arousal.
The purpose of this trial is to assess the feasibility of NMDA antagonist-assisted naltrexone
initiation in opioid dependent individuals. After administration of extended-release
naltrexone, participants will be followed for 4 weeks, and transitioned to appropriate care
subsequently (oral naltrexone, extended-release naltrexone).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03675386 -
Reducing Opioid Use for Chronic Pain Patients Following Surgery
|
N/A | |
| Completed |
NCT02593474 -
Medication-Assisted Treatment for Youth With Substance Use Disorders
|
Phase 1 | |
| Completed |
NCT02294253 -
Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
|
Phase 2/Phase 3 | |
| Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
| Completed |
NCT01592461 -
Starting Treatment With Agonist Replacement Therapies Follow-up Study
|
N/A | |
| Terminated |
NCT00768482 -
A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
|
Phase 3 | |
| Completed |
NCT01741350 -
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
|
N/A | |
| Terminated |
NCT04121546 -
Collaborative Care for Opioid Dependence And Pain Pilot Study
|
N/A | |
| Withdrawn |
NCT03368794 -
Naloxone to TReatment Entry in the Emergency Setting
|
N/A | |
| Completed |
NCT03447743 -
Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
|
Early Phase 1 | |
| Completed |
NCT04464421 -
SMART Effectiveness Trial
|
N/A | |
| Recruiting |
NCT04189523 -
Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage
|
N/A | |
| Completed |
NCT03305666 -
Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
|
Phase 4 | |
| Recruiting |
NCT04003948 -
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
|
Phase 2 | |
| Not yet recruiting |
NCT03813095 -
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
|
Phase 2 | |
| Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
| Completed |
NCT01895270 -
Improving Buprenorphine Detoxification Outcomes With Isradipine
|
Phase 1/Phase 2 | |
| Completed |
NCT01717963 -
Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway
|
Phase 3 | |
| Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
| Completed |
NCT01425060 -
Improving Effective Contraceptive Use Among Opioid-maintained Women
|
Phase 1 |